World Health Organization Sounds Warning Over Acute Lack of Weight-Loss Jabs
Fewer than 10% of people eligible to benefit from obesity jabs including Wegovy can access them, states the global health agency as it publishes its initial recommendations on the drugs.
Given in excess of 1,000,000,000 people worldwide currently classified as obese, it is calling for increased and just availability to this class of drugs.
Per forecasts, more than two billion are projected to be living with obesity by 2030 without intervention.
"Our latest guidelines affirms that excess weight is a long-term condition that can be treated with comprehensive and ongoing treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and distribution challenges are major barriers to broad access to the jabs that can help people shift significant weight, says the organization.
GLP-1 Therapy Shortage
Even under the present most favorable outlook, the production of GLP-1 therapies could only cover approximately 100 million people – fewer than 10% of the global need, per the WHO.
The advice encourages nations and manufacturers to expand access, via measures including licensing agreements.
Exclusive production rights on the active ingredient – the main component of the drug Wegovy – is due to expire in a number of nations in 2026.
The Way Weight-Loss Drugs Work
The injections mimick a biological compound to slow digestion, reduce hunger and increase feelings of fullness so users consume fewer calories.
Patients commonly see weight reduction within a few weeks of commencing the regular doses.
Studies indicates patients may regain a significant portion a year later of stopping the drug, because their typical hunger resume.
To be carrying excess weight raises your likelihood for experiencing health problems, such as diabetes, cardiovascular issues, brain attack, and specific malignancies.
Excess weight affects people in all nations and was associated with 3.7 million deaths worldwide in 2024, according to the health agency.
